CCredo Health offers an automated medical record retrieval platform for healthcare providers and payers that uses interoperability standards to automate the end-to-end process of obtaining patient records. The system connects to multiple data sources, gathers records, and delivers a complete, accurate set of information before the first visit so clinicians can start with a full view of the patient. It differentiates itself through end-to-end automation centered on standardized interoperability and a subscription-based model that may include premium features. The company aims to improve compliance, clinical understanding, and patient outcomes by ensuring timely, comprehensive records at the point of care.
Work here?Claim your company
Industries
Company Size
11-50
Company Stage
Seed
Total Funding
$8.3M
Headquarters
Denver, CO
Founded
2021
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$8.3M
Above
Industry Average
Funded Over
2 Rounds
Industry standards
Expands Optical Connectivity Portfolio to Include Silicon Photonics Photonic Integrated Circuits Credo Technology Group Holding Ltd (Credo) (NASDAQ: CRDO), an innovator in providing connectivity at scale through fast, reliable, and energy-efficient system solutions, today announced that it has completed its acquisition of DustPhotonics. DustPhotonics brings industry-leading silicon photonics photonic integrated circuit (SiPho PIC) technology for optical connectivity, deepening Credo’s optical interconnect portfolio across 800G, 1.6T, and 3.2T near-packaged optics (NPO) and co-packaged optics (CPO). With this technology, Credo is now positioned with a vertically integrated connectivity stack spanning SerDes, digital signal processing (DSP), silicon photonics, and system integration for scale-out and scale-up networks — addressing both electrical and optical interconnects across the full AI infrastructure buildout. Credo announced that it has completed its acquisition of DustPhotonics.
DustPhotonics adds PIC technology for 400G to 3.2T optics. Credo sees $500M+ optical revenue in fiscal 2027; closing is expected in Q2 2026.
"This investment is a testament to our commitment to fully support providers with the technology they need to succeed in value-based care," says Credo Founder and CEO Carm Huntress. .
Our solution not only improves patient outcomes, but directly affects providers' ability to accurately diagnose complex patients and speed up time to effective treatment. .
Find jobs on Simplify and start your career today
We update Credo's jobs every few hours, so check again soon!Browse all jobs
Industries
Company Size
11-50
Company Stage
Seed
Total Funding
$8.3M
Headquarters
Denver, CO
Founded
2021
Find jobs on Simplify and start your career today
We update Credo's jobs every few hours, so check again soon!Browse all jobs